J Jacquemier

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. pmc Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial
    Jocelyne Jacquemier
    Department of Molecular Oncology, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, 232, bd Ste Marguerite, Marseille, 13009, France
    Breast Cancer Res 13:R109. 2011
  2. pmc Kinome expression profiling and prognosis of basal breast cancers
    Renaud Sabatier
    Department of Molecular Oncology, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Institut Paoli Calmettes, 27 Bd Lei Roure, 13009 Marseille, France
    Mol Cancer 10:86. 2011
  3. pmc Breast cancer prognostic classification in the molecular era: the role of histological grade
    Emad A Rakha
    Department of Histopathology, Nottingham City Hospital NHS Trust, Nottingham University, Nottingham, UK
    Breast Cancer Res 12:207. 2010
  4. pmc CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines
    Gwladys Zabouo
    Institut Paoli Calmettes, Centre de Ressources Biologiques en Oncologie, Centre de Thérapie Cellulaire et Génique, Marseille, France
    Breast Cancer Res 11:R1. 2009
  5. pmc Primary leiomyosarcoma of the seminal vesicle: case report and review of the literature
    Cécile Cauvin
    Department of Radiotherapy, Institut Paoli Calmettes, 27 Bd Lei Roure, 13009, Marseille, France
    BMC Cancer 11:323. 2011
  6. pmc Genome profiling of ERBB2-amplified breast cancers
    Fabrice Sircoulomb
    Marseille Cancer Research Center, UMR891 Inserm, Institut Paoli Calmettes, Department of Molecular Oncology, Marseille, France
    BMC Cancer 10:539. 2010
  7. pmc Nectin-4 is a new histological and serological tumor associated marker for breast cancer
    Stéphanie Fabre-Lafay
    INSERM, UMR599, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    BMC Cancer 7:73. 2007
  8. pmc Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin
    Azza Ben Hamida
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm, Marseille, France
    BMC Cancer 8:28. 2008
  9. pmc Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers
    Anne Letessier
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm Institut Paoli Calmettes, Marseille, France
    BMC Cancer 6:245. 2006
  10. pmc Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer
    Jocelyne Jacquemier
    Département d Oncologie Moléculaire Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, UMR891 Inserm, IFR137, 232 Bd sainte Marguerite Marseille, France
    Breast Cancer Res 11:R23. 2009

Detail Information

Publications97

  1. pmc Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial
    Jocelyne Jacquemier
    Department of Molecular Oncology, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, 232, bd Ste Marguerite, Marseille, 13009, France
    Breast Cancer Res 13:R109. 2011
    ..We searched for prognostic and predictive markers for docetaxel's benefit...
  2. pmc Kinome expression profiling and prognosis of basal breast cancers
    Renaud Sabatier
    Department of Molecular Oncology, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Institut Paoli Calmettes, 27 Bd Lei Roure, 13009 Marseille, France
    Mol Cancer 10:86. 2011
    ..Kinases are often activated or overexpressed in cancers, and constitute targets for successful therapies. We sought to define a prognostic model of basal BCs based on kinome expression profiling...
  3. pmc Breast cancer prognostic classification in the molecular era: the role of histological grade
    Emad A Rakha
    Department of Histopathology, Nottingham City Hospital NHS Trust, Nottingham University, Nottingham, UK
    Breast Cancer Res 12:207. 2010
    ....
  4. pmc CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines
    Gwladys Zabouo
    Institut Paoli Calmettes, Centre de Ressources Biologiques en Oncologie, Centre de Thérapie Cellulaire et Génique, Marseille, France
    Breast Cancer Res 11:R1. 2009
    ..Studies of CD146 expression and function in breast cancer remain scarce except for a report concluding that CD146 could act as a tumor suppressor in breast carcinogenesis...
  5. pmc Primary leiomyosarcoma of the seminal vesicle: case report and review of the literature
    Cécile Cauvin
    Department of Radiotherapy, Institut Paoli Calmettes, 27 Bd Lei Roure, 13009, Marseille, France
    BMC Cancer 11:323. 2011
    ..Primary leiomyosarcoma of the seminal vesicle is exceedingly rare...
  6. pmc Genome profiling of ERBB2-amplified breast cancers
    Fabrice Sircoulomb
    Marseille Cancer Research Center, UMR891 Inserm, Institut Paoli Calmettes, Department of Molecular Oncology, Marseille, France
    BMC Cancer 10:539. 2010
    ..They are associated with a poor prognosis but can benefit from targeted therapy. A better knowledge of these BCs, genomically and biologically heterogeneous, may help understand their behavior and design new therapeutic strategies...
  7. pmc Nectin-4 is a new histological and serological tumor associated marker for breast cancer
    Stéphanie Fabre-Lafay
    INSERM, UMR599, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    BMC Cancer 7:73. 2007
    ..Nectins are cell adhesion molecules involved in the regulation of epithelial physiology. We present here Nectin-4/PVRL4 as a new histological and serological tumor associated marker for breast carcinoma...
  8. pmc Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin
    Azza Ben Hamida
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm, Marseille, France
    BMC Cancer 8:28. 2008
    ..The aim of this study was to determine the distribution of molecular subtypes in IBC and identify factors that may explain the poor prognosis of IBC...
  9. pmc Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers
    Anne Letessier
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm Institut Paoli Calmettes, Marseille, France
    BMC Cancer 6:245. 2006
    ..Amplification status may provide diagnostic and prognostic information and may lead to new treatment strategies. Chromosomal regions 8p12, 8q24, 11q13, 17q12 and 20q13 are recurrently amplified in breast cancers...
  10. pmc Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer
    Jocelyne Jacquemier
    Département d Oncologie Moléculaire Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, UMR891 Inserm, IFR137, 232 Bd sainte Marguerite Marseille, France
    Breast Cancer Res 11:R23. 2009
    ..The aim of this study was to identify the best predictors of success of hormonal therapy...
  11. ncbi request reprint Histological type and syncytial growth pattern affect E-cadherin expression in a multifactorial analysis of a combined panel of sporadic and BRCA1-associated breast cancers
    J Jacquemier
    Department of Pathology, Paoli Calmettes Institute, Marseille, France
    Int J Cancer 83:45-9. 1999
    ..0001), in agreement with previous results, and syncytial growth pattern (SGP) (p = 0.01). The latter result provides a biological basis for SGP, the cardinal feature of medullary breast carcinoma...
  12. ncbi request reprint Prognosis of breast-carcinoma lymphagenesis evaluated by immunohistochemical investigation of vascular-endothelial-growth-factor receptor 3
    J Jacquemier
    Pathology Department, Institut Paoli Calmettes, Marseille, France
    Int J Cancer 89:69-73. 2000
    ..5 and of MLC, 40.5. There was no quantitative correlation between these 2 parameters. The MVC but not the MLC had a prognostic value in overall survival. Neither the MLC nor the MVC had any correlation with axillary-lymph-node invasion...
  13. ncbi request reprint [Small but high throughput: how "tissue-microarrays" became a favorite tool for pathologists and scientists]
    Jocelyne Jacquemier
    Département d Oncologie Moléculaire, Institut Paoli Calmettes, 232 Bd de Sainte Marguerite, 13273 Marseille Cedex 9, France
    Ann Pathol 23:623-32. 2003
    ..This Article provides a short review of this technology, and points out several aspects of the TMA construction and its applications for clinical research...
  14. ncbi request reprint Typical medullary breast carcinomas have a basal/myoepithelial phenotype
    Jocelyne Jacquemier
    Marseille Cancer Institute, Molecular Oncology Department, UMR599 INSERM and Paoli Calmettes Institute, Marseille, France
    J Pathol 207:260-8. 2005
    ..In multivariate analysis with logistic regression, TMBC was defined by the association of P-cadherin (R=2.29), MIB1 > 50 (R=3.80), ERBB2 negativity (R=2.24) and p53 positivity (RR=1.45)...
  15. ncbi request reprint Association of angiogenesis and poor prognosis in node-positive patients receiving anthracycline-based adjuvant chemotherapy
    P Viens
    Medical Oncology Department, Institut Paoli Calmettes, Universite de la Mediterranee, Marseille, France
    Breast Cancer Res Treat 54:205-12. 1999
    ..The purpose of this study was to evaluate the influence of angiogenesis in node-positive breast cancer and particularly its potential impact on adjuvant chemotherapy...
  16. ncbi request reprint Outpatient sequential high dose alkylation with stem cell support for patients with advanced breast cancer: a phase I-II study
    D Genre
    Institut Paoli Calmettes, Marseilles, France
    Anticancer Res 20:2033-40. 2000
    ..The objective response rate was 48% (11% CR, 37% PR). We recommended T and B at a dose of 600 mg/m2 to conduct a phase II study in metastatic breast cancer and even to administer B before T...
  17. ncbi request reprint High-dose alkylating agents with autologous hematopoietic stem cell support and trastuzumab in ERBB2 overexpressing metastatic breast cancer: a feasibility study
    A Goncalves
    Department of Medical Oncology, Institut Paoli Calmettes, 13273 Marseille Cedex 9, France
    Anticancer Res 25:663-7. 2005
    ..We investigated the feasibility of combining high-dose alkylating agents with autologous hematopoietic stem cell (AHSC) support and trastuzumab in ERBB2 overexpressing MBC...
  18. ncbi request reprint Equivalent survival in patients with advanced stage IB-II and III-IVA cervical cancer treated by adjuvant surgery following chemoradiotherapy
    X Carcopino
    Department of Surgery, Institut Paoli Calmettes, 232 Bd Sainte Marguerite, 13009 Marseille, France
    Eur J Surg Oncol 34:569-75. 2008
    ..To evaluate survival in patients with advanced cervical cancer who underwent surgery after concurrent chemoradiotherapy...
  19. ncbi request reprint Local and distant failures after limited surgery with positive margins and radiotherapy for node-negative breast cancer
    D Cowen
    Department of Radiation Oncology, Institut Paoli Calmettes Cancer Center and Reseau Convergence Cancer R2C, Marseille, France
    Int J Radiat Oncol Biol Phys 47:305-12. 2000
    ..To determine the outcome of patients with positive margins after lumpectomy for breast cancer and to address the issue of the relationship between local recurrences and distant metastasis in the absence of chemotherapy...
  20. ncbi request reprint PS2 expression in BRCA1-associated breast cancers
    E Charafe-Jauffre
    Department de Pathologie Institut Paoli-Calmettes, Marseille, France
    Anticancer Res 21:2877-81. 2001
    ..CONCLUSION: pS2-expression in BRCA1-BC's was significantly different from sporadic breast cancer (p<0.0001) and correlated in a multivariate analysis with the same factors in sporadic and BRCA1-BC's but not with BRCA1 mutation...
  21. ncbi request reprint Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment
    F Bertucci
    Department of Medical Oncology, Institut Paoli Calmettes, Marseille Cedex 09, France
    Bone Marrow Transplant 33:913-20. 2004
    ..These results and comparisons with other series of patients suggest a role for HDC with HSCS as part of the therapeutic approach in IBC. Further prospective studies are required to confirm it...
  22. ncbi request reprint ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines
    C Ginestier
    UMR599 Inserm, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, Marseille, France
    Oncogene 26:7163-9. 2007
    ..We show that sensitivity to trastuzumab is frequently associated with the expression of a phosphorylated ERBB2 protein...
  23. doi request reprint [Margin status in invasive breast cancer]
    G Houvenaeghel
    Institut Paoli Calmettes, Marseille, France
    Bull Cancer 95:1161-70. 2008
    ..The influence of extensive intraductal component on local recurrence risk has been studied. Several factors are correlated and to define independent factors seem to be interesting...
  24. ncbi request reprint Contribution of surgery in patients with bulky residual disease after chemoradiation for advanced cervical carcinoma
    G Houvenaeghel
    Department of Surgery, Institut Paoli Calmettes, 232 Bd Sainte Marguerite, Marseilles, France
    Eur J Surg Oncol 33:498-503. 2007
    ..To report the outcome of 30 patients who underwent surgery after concomitant chemoradiation for locally advanced cervical cancer with residual disease > or = 2 cm...
  25. ncbi request reprint Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer
    A Letessier
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm et Institut Paoli Calmettes, Marseille, France
    Oncogene 26:298-307. 2007
    ..Loss of Afadin had prognostic impact, suggesting that AF-6 may be a TSG. Loss of Afadin was correlated with loss of FHIT expression, suggesting fragility of FRA6E and FRA3B in a certain proportion of breast tumors...
  26. ncbi request reprint Gene expression profiling of breast cell lines identifies potential new basal markers
    E Charafe-Jauffret
    Marseille Cancer Institute, Laboratory of Molecular Oncology, Inserm Institut Paoli Calmettes, Marseille, France
    Oncogene 25:2273-84. 2006
    ....
  27. pmc A seven-gene prognostic model for platinum-treated ovarian carcinomas
    R Sabatier
    Department of Molecular Oncology, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Institut Paoli Calmettes, 13009 Marseille, France
    Br J Cancer 105:304-11. 2011
    ..We analysed gene expression profiles of ovarian carcinomas to identify a multigene expression model associated with survival after platinum-based therapy...
  28. ncbi request reprint Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'
    Emmanuelle Charafe-Jauffret
    Département d Oncologie Moléculaire, Institut Paoli Calmettes et U119 INSERM, IFR57, Marseille, France
    J Pathol 202:265-73. 2004
    ..0049 for OS and p < 0.0001 for DFS). In conclusion, an immunophenotypic signature was suggested for IBC. This could help to determine the worst cases, independent of clinical criteria...
  29. ncbi request reprint Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy
    A Goncalves
    Department of Molecular Pharmacology, Institut Paoli Calmettes, UMR599 Institut National de la Santé et de la Recherche Médicale INSERM, Marseille, France
    Oncogene 25:981-9. 2006
    ..Therefore, postoperative serum protein pattern may have an important prognostic value in high-risk EBC...
  30. pmc Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles
    F Bertucci
    INSERM UMR891, Centre de Recherche en Cancerologie de Marseille, Institut Paoli Calmettes, Marseille, France
    Oncogene 27:5359-72. 2008
    ..Although ILCs and IDCs share common alterations, our data show that ILCs and IDCs could be distinguished on the basis of their genomic and expression profiles suggesting that they evolve along distinct genetic pathways...
  31. ncbi request reprint WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type
    F Ugolini
    Laboratoire d Oncologie Moleculaire, INSERM U 119, IFR 57, 27 Boulevard Lei Roure, 13009, Marseille, France
    Oncogene 20:5810-7. 2001
    ..Conversely, the maintenance of SFRP1 in carcinomas is correlated with the presence of lymphoplasmocytic stroma. No significant association was observed between SFRP1 status and the level of apoptosis in tumoral cells...
  32. pmc First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial)
    P Viens
    Institut Paoli Calmettes, Marseille, France
    Br J Cancer 81:449-56. 1999
    ..High-dose chemotherapy with repeated BSC transplantation is feasible with acceptable toxicity in IBC. Pathological response rate is encouraging but has to be confirmed by final outcome...
  33. ncbi request reprint Identification and validation of an ERBB2 gene expression signature in breast cancers
    Francois Bertucci
    Département d Oncologie Moléculaire, Institut Paoli Calmettes and UMR119 Inserm, IFR57, and Faculté de Médecine, Universite de la Mediterranee, Marseille, France
    Oncogene 23:2564-75. 2004
    ..Some correlations were validated at the protein level using IHC on tissue microarrays. The GES was able to distinguish ERBB2-negative and -positive cancer samples, as well as FISH-negative and FISH-positive ERBB2 2+ IHC samples...
  34. ncbi request reprint Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation: computed efficacy, effectiveness and impact
    F Eisinger
    Department of Genetic Oncology and Cancer Control INSERM EPI 9939, Marseille, France
    Int J Oncol 18:5-10. 2001
    ..Since autonomy of choice is the root of western ethics, cancer prone women should be informed about the low but valuable expected reduction of incidence of breast cancer using Tamoxifen preventive therapy...
  35. ncbi request reprint [Surgical resection after chemotherapy for advanced cervical carcinoma]
    G Houvenaeghel
    Service de Chirurgie Oncologique 2, Institut Paoli Calmettes, 232, boulevard Sainte Marguerite, 13273 Marseille Cedex, France
    Cancer Radiother 10:471-6. 2006
    ..The aim of this study is to discuss surgery after chemoradiotherapy in terms of rate of morbidity and residual tumor, rate of pelvic disease control, overall survival and disease-free survival...
  36. ncbi request reprint [Impact of recent oncogenetic progress on the management of high risk breast cancer patients: the example of BRCA1 and BRCA2 genes]
    H Sobol
    Département d Oncologie Génétique INSERM CRI 9703, Institut Paoli Calmettes, Marseille, France
    Ann Endocrinol (Paris) 59:459-64. 1998
    ..These elements may be of valuable help in the design of strategies in the medical management of cancer prone individuals...
  37. ncbi request reprint Overexpression of erb B2 remains a major risk factor in non-metastatic breast cancers treated with high-dose alkylating agents and autologous stem cell transplantation
    A C Braud
    Department of Medicine, Institut Paoli Calmettes, Marseille, France
    Bone Marrow Transplant 29:753-7. 2002
    ..74 to 16.03) survival. These results suggest that poor prognosis of erb B2 overexpression is unchanged after HDC with alkylating agents but a possible benefit may exist in these patients with the additional monoclonal antibody, herceptin...
  38. doi request reprint Sentinel lymphadenectomy for the staging of clinical axillary node-negative breast cancer before neoadjuvant chemotherapy
    J P Menard
    Department of Surgery, Institut Paoli Calmettes, Regional Cancer Center, 232 Bvd, Sainte Margueritte, 13273 Marseille Cedex 9, France
    Eur J Surg Oncol 35:916-20. 2009
    ..Several authors reported sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NC). Nevertheless, the ideal time of SLNB is still a matter of debate...
  39. ncbi request reprint Integrated profiling of basal and luminal breast cancers
    José Adélaïde
    Marseille Cancer Research Center, Department of Molecular Oncology, Institut Paoli Calmettes and UMR599 Institut National de la Santé et de la Recherche Médicale, Marseille, France
    Cancer Res 67:11565-75. 2007
    ..Finally, among 10p candidate oncogenes associated with basal subtype, we validated CDC123/C10orf7 protein as a basal marker...
  40. pmc p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results
    J Jacquemier
    , Institut Paoli Calmettes, Marseille, France
    Br J Cancer 69:846-52. 1994
    ..In this series p53 expression was not a marker of early recurrence...
  41. doi request reprint A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis
    G Houvenaeghel
    Institut Paoli Calmettes, Marseille, France
    Eur J Surg Oncol 35:690-5. 2009
    ..This nomogram is not accurate for SN micrometastasis. The purpose of our study was to determine a nomogram for predicting the likelihood of NSN involvement in breast cancer patients with a SN micrometastasis...
  42. ncbi request reprint [Pelvic posterior exenteration with immediate colo-rectal anastomosis: is it justified and feasible in advanced stage ovarian carcinoma?]
    M Buttarelli
    Service de Chirurgie Oncologique 2, Institut Paoli Calmettes, 232, boulevard Sainte Marguerite, BP 156, 13273 Marseille Cedex 09, France
    Ann Chir 131:431-6. 2006
    ..The aim of this study is to show that the removal of the rectum is not an obstacle to implement an optimal surgery in advanced epithelial cancer of the ovary...
  43. ncbi request reprint Occult tumor cell contamination in patients with stage II/III breast cancer receiving sequential high-dose chemotherapy
    F Viret
    Department of Medicine, Institut Paoli Calmettes, Marseille, France
    Bone Marrow Transplant 32:1059-64. 2003
    ..Three of these eight patients relapsed. This study has confirmed that contamination of apheresis products remains a rare event, which does not seem to affect clinical evolution, even when reinfused into the patient...
  44. doi request reprint Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer
    Frederique Penault-Llorca
    Department of Pathology, Centre Jean Perrin, EA 4233, Université d Allvergne Clermont 1, Clermont Ferrand 63000, France
    J Clin Oncol 27:2809-15. 2009
    ..89; 95% CI, 0.47 to 1.66; P = .71). CONCLUSION Ki67 expression identifies a subset of patients with ER-positive breast cancer who could be sensitive to docetaxel treatment in the adjuvant setting...
  45. ncbi request reprint Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer
    Christophe Ginestier
    Département d Oncologie Moléculaire, Institut Paoli Calmettes and U119 Inserm, IFR57, Marseille, France
    Int J Cancer 107:854-62. 2003
    ..37 (1.21-4.64; p = 0.03). Thus, among the patients who present with tumors of apparent good prognosis, FHIT is an independent prognostic factor that distinguishes a subgroup of patients who could benefit from adjuvant treatment...
  46. ncbi request reprint Inflammatory breast cancers in Tunisia and France show similar immunophenotypes
    Emmanuelle Charafe-Jauffret
    Institut de Cancérologie de Marseille, Département d Oncologie Moléculaire, Institut Paoli Calmettes et UMR599 Inserm, IFR137 Marseille, France
    Breast 16:352-8. 2007
    ..It is thought that IBC occurs with a high frequency in Tunisia. The aim of this study is to evaluate this signature on a Tunisian series...
  47. ncbi request reprint Comparative multi-methodological measurement of ERBB2 status in breast cancer
    Christophe Ginestier
    Département d Oncologie Moléculaire, Institut Paoli Calmettes et U119 INSERM, IFR57, Marseille, France
    J Pathol 202:286-98. 2004
    ..A new combined IHC score based on the association of two selected anti-ERBB2 antibodies (HercepTest trade mark and TAB250) and a dual scale for improved assessment of ERBB2 protein expression, particularly in 2+ cases, are proposed...
  48. ncbi request reprint [Interest of sentinel lymph node biopsy for the staging of ductal carcinoma in situ]
    M Buttarelli
    Service de chirurgie oncologique, Institut Paoli Calmettes, 232 Boulevard Sainte Marguerite, BP 156, 13009 Marseille cedex 9, France
    Ann Chir 129:508-12. 2004
    ..The aim of this study was to define the interest of sentinel lymph node biopsy (SLNB) for the staging of ductal carcinoma in situ (DCIS) and DCIS with micro-invasion (DCISM) in patients with breast carcinoma...
  49. pmc c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays
    S Garcia
    Department of Pathology, Centre Hospitalo Universitaire Nord, Marseille, France
    Br J Cancer 96:329-35. 2007
    ..Automated image analysis of TMA proved to be a valuable tool for high-throughput immunohistochemical quantification of the expression of intratumorous protein markers...
  50. ncbi request reprint Moesin expression is a marker of basal breast carcinomas
    Emmanuelle Charafe-Jauffret
    Laboratory of Molecular Oncology, Marseille Cancer Research Institute, UMR599 Inserm Institut Paoli Calmettes, Marseille, France
    Int J Cancer 121:1779-85. 2007
    ..014). In multivariate analysis, Moesin expression was nearly an independent prognostic marker of poor outcome as shown by Cox proportional hazard model in patients without lymph node metastasis (p = 0.052, HR = 2.38, CI 95[0.99-5.69])...
  51. ncbi request reprint Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype
    Stephane Garcia
    Department of Pathology, Centre Hospitalo Universitaire Nord, 13916 Marseille, France
    Hum Pathol 38:830-41. 2007
    ....
  52. ncbi request reprint Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy
    Francois Bertucci
    Département d Oncologie Moléculaire, Institut Paoli Calmettes and UMR599 Institut National de la Santé et de la Recherche Médicale, IFR137, Marseille, France
    Cancer Res 64:8558-65. 2004
    ..These results show the potential of gene expression profiling to contribute to a better understanding of IBC, and to provide new diagnostic and predictive factors for IBC, as well as for potential therapeutic targets...
  53. pmc Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers
    Christophe Ginestier
    Département d Oncologie Moléculaire, Institut Paoli Calmettes and Institut National de la Santé et de la Recherche Medical U119, IFR57, Marseille, France
    Am J Pathol 161:1223-33. 2002
    ..Thus, differences extended to clinical prognostic information obtained by the two methods underlining their complementarity and the need for a global molecular analysis of tumors at both the RNA and protein levels...
  54. doi request reprint Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions
    G MacGrogan
    Department of Pathology, Institut Bergonie, Bordeaux, France
    Histopathology 52:689-97. 2008
    ..To assess the impact of cytokeratin (CK) 5/6 and E-cadherin immunohistochemistry on diagnostic agreement of non-invasive proliferative breast lesions...
  55. ncbi request reprint Nonvisualization of axillary sentinel node during lymphoscintigraphy: is there a pathologic significance in breast cancer?
    Isabelle Brenot-Rossi
    Department of Nuclear Medicine, Institut Paoli Calmettes, Regional Cancer Center, Universite de la Mediterranee, 232 Boulevard Sainte Marguerite, 13273 Marseille Cedex 9, France
    J Nucl Med 44:1232-7. 2003
    ..The aim of this study was to define the factors associated with nonvisualization of a sentinel node (SN) in the axilla area during preoperative lymphoscintigraphy...
  56. pmc Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes
    Anthony Goncalves
    Department of Molecular Pharmacology, Marseille Research Cancer Center, Marseille, France
    Mol Cell Proteomics 7:1420-33. 2008
    ..Our study shows the potential of integrated genomics and proteomics profiling to improve molecular knowledge of complex tumor phenotypes and identify biomarkers with valuable diagnostic or prognostic values...
  57. ncbi request reprint Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulators
    Nathalie Conte
    Département d Oncologie Moléculaire, U119 INSERM, 27 Bd Lei Roure, 13009, Marseille, France
    Oncogene 21:5619-30. 2002
    ..We speculate that down-regulation of TACC1 may alter the control of mRNA homeostasis in polarized cells and participates in the oncogenic processes...
  58. ncbi request reprint Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors
    Marine Gilabert
    Oncologie Médicale, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, INSERM U891, 232, boulevard Sainte Marguerite, 13009 Marseille, France
    Anticancer Res 31:1079-86. 2011
    ....
  59. doi request reprint How different are luminal A and basal breast cancers?
    Francois Bertucci
    Département d Oncologie Moléculaire, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Marseille, France
    Int J Cancer 124:1338-48. 2009
    ....
  60. ncbi request reprint Value of the sentinel lymph node procedure in patients with large size breast cancer
    Loic Lelievre
    Department of Surgery, Institut Paoli Calmettes, 232 Bd Sainte Marguerite, Marseilles, France
    Ann Surg Oncol 14:621-6. 2007
    ..Widely used in routine for small breast cancers, the sentinel lymph node (SN) biopsy is still discussed in tumors >or= 3 cm...
  61. ncbi request reprint [Impact on the quality of pathology reports in the R2c cancer network: analysis of 4521 pathology reports of primary breast tumors]
    Valerie Jeanne Bardou
    Département d information médicale et biostatistique, Institut Paoli Calmettes, 232, boulevard Sainte Marguerite, 13273 Marseille Cedex 09
    Bull Cancer 93:1033-8. 2006
    ..Lastly, the shared liability in oncology probably has an indirect impact on practices of non-member pathologists...
  62. ncbi request reprint Micrometastases in sentinel lymph node in a multicentric study: predictive factors of nonsentinel lymph node involvement--Groupe des Chirurgiens de la Federation des Centres de Lutte Contre le Cancer
    Gilles Houvenaeghel
    Institut Paoli Calmettes, Marseille, France
    J Clin Oncol 24:1814-22. 2006
    ..To determine the rate of nonsentinel lymph node (NSN) involvement at axillary lymph node dissection (ALND) and predictive factors of this involvement following detection of micrometastasis in sentinel nodes (SN)...
  63. ncbi request reprint Prognosis of breast cancer and gene expression profiling using DNA arrays
    Francois Bertucci
    Département d Oncologie Moléculaire, TAGC, Institut Paoli Calmettes IPC, IFR57, Marseille, France
    Ann N Y Acad Sci 975:217-31. 2002
    ..We also showed that nylon DNA arrays with radioactive detection are associated with excellent sensitivity, an advantage in clinical situations where the amount of available material is limited...
  64. doi request reprint Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status
    Anthony Goncalves
    Oncologie Médicale, Centre de Recherche en Cancerologie de Marseille, INSERM U891, Institut Paoli Calmettes, 232, boulevard Sainte Marguerite, Marseille 13000, France
    Anticancer Drugs 20:946-52. 2009
    ..The subset of HER2-negative, HR-negative (triple-negative) has a very poor outcome, and innovative therapies are eagerly awaited for these patients...
  65. pmc Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer
    Emmanuelle Charafe-Jauffret
    Department of Molecular Oncology, Institut Paoli Calmettes UMR891 Institut National de la Sante et de la Recherche Medicale, Universite de la Mediterranee, Marseille Cancer Research Center, Marseille, France
    Clin Cancer Res 16:45-55. 2010
    ..To examine the role of cancer stem cells (CSC) in mediating metastasis in inflammatory breast cancer (IBC) and the association of these cells with patient outcome in this aggressive type of breast cancer...
  66. ncbi request reprint ETV6 gene rearrangements in invasive breast carcinoma
    Anne Letessier
    Marseille Cancer Institute, Laboratory of Molecular Oncology, Institut Paoli Calmettes and UMR599 INSERM, Marseille, France
    Genes Chromosomes Cancer 44:103-8. 2005
    ..Of these samples, signal of sufficient quality for screening by FISH was obtained for 356. Five cases (one lobular, one nontypical secretory, one mixed, and two ductal carcinomas) showed ETV6 rearrangement...
  67. doi request reprint Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer
    Francois Bertucci
    Département d Oncologie Moléculaire, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Institut Paoli Calmettes IPC, Marseille, France
    Breast Cancer Res Treat 127:363-73. 2011
    ..Our predictor refines the prediction of metastasis-free survival after adjuvant anthracycline-based CT and might help tailoring adjuvant CT regimens...
  68. ncbi request reprint [Inflammatory breast carcinoma: towards molecular characterization?]
    Emmanuelle Charafe-Jauffret
    Département de biopathologie, Institut Paoli Calmettes, Marseille
    Ann Pathol 23:564-9. 2003
    ..It has been shown to be lost in IBC and could control tumor growth, invasion, and angiogenesis. This paper summarizes current knowledge on IBC and describes a new basis for a molecular definition of IBC...
  69. pmc An assessment of extensive intraductal component as a risk factor for local recurrence after breast-conserving therapy
    J Jacquemier
    Department of Anatomic Pathology, Marseille Cancer Institute, France
    Br J Cancer 61:873-6. 1990
    ..The presence of EIC had no influence on overall survival, on median time to local recurrence, or on short-term survival after local failure. The usefulness of EIC as a risk factor for local recurrence is discussed...
  70. doi request reprint Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis
    Pascal Finetti
    UMR599 Inserm, Institut Paoli Calmettes, Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    Cancer Res 68:767-76. 2008
    ..The identification of luminal A cases of poor prognosis should help select appropriate treatment, whereas the identification of a relevant kinase set provides potential targets...
  71. ncbi request reprint Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis
    Stephane Garcia
    Department of Pathology, Centre Hospitalo Universitaire, Hopital Nord, Marseille, France
    Int J Oncol 31:49-58. 2007
    ....
  72. ncbi request reprint A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene
    José Adélaïde
    Département d Oncologie Moléculaire, Laboratoires de Cytogénétique Moléculaire et de Pathologie Moléculaire, U119 Institut National de la Santé et de la Recherche Médicale INSERM and Institut Paoli Calmettes IPC, Marseille, France
    Genes Chromosomes Cancer 37:333-45. 2003
    ..PCR analysis of reverse-transcribed cell line RNAs revealed an extensive complexity of the NRG1 transcripts but failed to detect a consistent pattern of mRNA isoforms in the cell lines with NRG1 breakpoint...
  73. ncbi request reprint Gene expression profiling identifies molecular subtypes of inflammatory breast cancer
    Francois Bertucci
    Institut de Cancérologie de Marseille, Laboratoire d Oncologie Moleculaire, Institut Paoli Calmettes and UMR599 Institut National de la Santé et de la Recherche Médicale, IFR137, France
    Cancer Res 65:2170-8. 2005
    ....
  74. ncbi request reprint [Towards an integrated cellular and molecular: definition of breast cancers]
    Emmanuelle Charafe-Jauffret
    UMR 599 Inserm, Institut Paoli Calmettes, Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancérologie de Marseille et Université de la Méditerranée, 27, boulevard Lei Roure, 13009 Marseille, France
    Med Sci (Paris) 23:626-32. 2007
    ..These combined studies allow a new integrated cellular and molecular definition of breast cancers and a conceptual basis that will help the management of the disease...
  75. ncbi request reprint Gene expression profiles of poor-prognosis primary breast cancer correlate with survival
    Francois Bertucci
    Département d Oncologie Moléculaire TAGC, U 119 INSERM, Marseille, France
    Hum Mol Genet 11:863-72. 2002
    ..Furthermore, the characterization of discriminator genes might accelerate the development of new specific and alternative therapies, allowing more rationally tailored treatments that are potentially more efficient and less toxic...
  76. ncbi request reprint Protein expression profiling identifies subclasses of breast cancer and predicts prognosis
    Jocelyne Jacquemier
    Institut de Cancérologie de Marseille, Département d Oncologie Moléculaire, Institut Paoli Calmettes and UMR599 INSERM, 27 Boulevard Lei Roure, Marseille, France
    Cancer Res 65:767-79. 2005
    ..These results show that protein expression profiling may be a clinically useful approach to assess breast cancer heterogeneity and prognosis in stage I, II, or III disease...
  77. ncbi request reprint Characterization of the region of the short arm of chromosome 8 amplified in breast carcinoma
    A Dib
    Laboratoire d Oncologie Moleculaire, U 119 INSERM, Marseille, France
    Oncogene 10:995-1001. 1995
    ..The precise localization and YAC cloning of the core of the amplicon will allow to isolate a putative oncogene involved in mammary carcinogenesis...
  78. ncbi request reprint Junctional recruitment of mammalian Scribble relies on E-cadherin engagement
    Christel Navarro
    Marseille Cancer Institute, Molecular Pharmacology, UMR 599 Inserm Institut Paoli Calmettes, 27 boulevard Lei Roure 13009 Marseille, France
    Oncogene 24:4330-9. 2005
    ..Our data provide additional insights on the modalities of recruitment of hScrib at the cell-cell junctions, and establish a potential link between the E-cadherin and hScrib tumor suppressors...
  79. ncbi request reprint How to best classify breast cancer: conventional and novel classifications (review)
    Emmanuelle Charafe-Jauffret
    Marseille Cancer Institute, Laboratory of Molecular Oncology, UMR599 Inserm, Marseille, France
    Int J Oncol 27:1307-13. 2005
    ..We have tried here to confront the conventional existing classifications with this new molecular taxonomy. It is likely that using all types of classification together will help in the management of breast cancer...
  80. ncbi request reprint High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study
    Magali Lacroix-Triki
    Department of Pathology, Institut Claudius Regaud, 20 24 rue du Pont saint Pierre, 31052 Toulouse Cedex, France
    Eur J Cancer 42:2946-53. 2006
    ..82). As expected, the score 2+ group showed poor agreement (kappa=0.38). A quality assurance process showed that ring studies and adherence to national guidelines greatly improve inter-observer reproducibility...
  81. doi request reprint Sonographic appearance of a metastasis to the breast from a cerebellar medulloblastoma
    Frédéric Ternier
    Department of Radiology, Institut Paoli Calmettes, 232 Bvd Sainte Margueritte, 13009 Marseille, France
    J Clin Ultrasound 38:335-7. 2010
    ..It is important to distinguish primary breast cancer from metastasis to the breast, because the therapeutic options as well as the prognosis are very different...
  82. ncbi request reprint Loss of heterozygosity at microsatellite markers from region p11-21 of chromosome 8 in microdissected breast tumor but not in peritumoral cells
    Emmanuelle Charafe-Jauffret
    Département d Oncologie Moléculaire, Institut Paoli Calmettes IPC, Marseille, France
    Int J Oncol 21:989-96. 2002
    ..In most samples, the TACC1 gene product was downregulated in tumor cells as compared to normal cells. Our results show that the centromeric portion of chromosome arm 8p is frequently altered in breast tumor cells...
  83. doi request reprint 18 Fluoro-2deoxy-d-glucose-positron emission tomography and locally advanced cervical cancer
    Stephanie Motton
    Institut Paoli Calmettes, Marseille, France
    Int J Gynecol Cancer 19:8-12. 2009
    ....
  84. ncbi request reprint TACC1-chTOG-Aurora A protein complex in breast cancer
    Nathalie Conte
    Department of Molecular Oncology, U119 INSERM, Institut Paoli Calmettes, IFR57, Marseille, France
    Oncogene 22:8102-16. 2003
    ....
  85. ncbi request reprint [Tissue microarrays a powerful tool in transfer and quality control in oncology]
    Jocelyne Jacquemier
    Département d Oncologie Moléculaire, Institut Paoli Calmettes, 232, Bd de Sainte Marguerite, 13273 Marseille Cedex 9
    Bull Cancer 90:31-8. 2003
    ..This article provides a short review of this technology, and points out several aspects of the TMA construction and its applications for clinical research...
  86. ncbi request reprint A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin 1/heregulin gene
    Huai En Huang
    Cancer Genomics Program, Hutchison MRC Research Centre, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    Cancer Res 64:6840-4. 2004
    ..They were, like breast tumors in general, mainly ErbB2 low (11 of 13 were low) and estrogen receptor positive (11 of 13 positive)...
  87. ncbi request reprint The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2
    Sunil R Lakhani
    Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research and the Royal Marsden Hospital, London, United Kingdom
    J Clin Oncol 20:2310-8. 2002
    ..This study evaluates the immunohistochemical profiles of tumors arising in patients with mutations in these genes...
  88. ncbi request reprint [Sentinel lymph node negative breast cancer larger than 30 mm: is axillary lymph node dissection constantly necessary?]
    Gilles Houvenaeghel
    Départements de chirurgie, Institut Paoli Calmettes, 232 Bd Sainte Marguerite, 13006 Marseille Cedex 9
    Bull Cancer 91:S221-5. 2004
    ..This series results suggest than AD could be avoided for negative SLNB tumors up to 50 mm at pathologic examination in patients with clinically-measured tumor smaller than 30 mm...
  89. ncbi request reprint Comprehensive profiling of 8p11-12 amplification in breast cancer
    Véronique Gelsi-Boyer
    Marseilles Cancer Institute, Department of Molecular Oncology, UMR599 Institut National de la Sante et de la Recherche Medicale, France
    Mol Cancer Res 3:655-67. 2005
    ..Finally, we show that 8p11-12 amplification has a pejorative effect on survival in breast cancer...
  90. ncbi request reprint Residual pelvic lymph node involvement after concomitant chemoradiation for locally advanced cervical cancer
    Gilles Houvenaeghel
    Department of Surgery, Institut Paoli Calmettes, 232 Bd Sainte Marguerite, 13009 Marseille, France
    Gynecol Oncol 102:74-9. 2006
    ..Adjuvant surgery is optional. The aim of this study was to evaluate the rate of residual positive pelvic lymph nodes after chemoradiation...
  91. ncbi request reprint Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers
    Francois Bertucci
    Institut de Cancérologie de Marseille, Département d Oncologie Moléculaire, Institut Paoli Calmettes et Unité Mixte de Recherche 599 Institut National de la Santé et de la Recherche Médicale, Marseilles, France
    Cancer Res 66:4636-44. 2006
    ..Finally, MBCs overexpress a series of genes located on the 12p13 and 6p21 chromosomal regions known to contain pluripotency genes. Our results contribute to a better understanding of MBC and of mammary oncogenesis in general...
  92. ncbi request reprint [What is new about sentinel lymph node biopsy in breast cancer?]
    Gilles Houvenaeghel
    Departement de Chirurgie, Institut Paoli Calmettes, 232 Bd Sainte Marguerite, 13006 Marseille Cedex 9
    Bull Cancer 91:S216-20. 2004
    ..Classification for micro-metastasis, isolated cells and macro-metastasis in sentinel lymph node was suggested but their immunohistochimic detection and prognostic impact are unclear. These parts are discussed in this article...
  93. ncbi request reprint Prognosis and gene expression profiling of 20q13-amplified breast cancers
    Christophe Ginestier
    Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancerologie de Marseille, UMR599 Inserm, Marseilles, France
    Clin Cancer Res 12:4533-44. 2006
    ..Amplification of chromosomal region 20q13 occurs in breast cancer but remains poorly characterized...
  94. ncbi request reprint [Risk of stage underestimation of breast cancer by sentinel lymph node biopsy method]
    Gilles Houvenaeghel
    Institut Paoli Calmettes, 232, boulevard de Sainte Marguerite, 13273 Marseille Cedex 9
    Bull Cancer 90:467-73. 2003
    ..SLN biopsy indication could he improved according these data which could be obtain pre-operatively by micro-biopsy...
  95. ncbi request reprint Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype
    Sunil R Lakhani
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 11:5175-80. 2005
    ..To investigate the proportion of breast cancers arising in patients with germ line BRCA1 and BRCA2 mutations expressing basal markers and developing predictive tests for identification of high-risk patients...
  96. pmc ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
    Christophe Ginestier
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
    Cell Stem Cell 1:555-67. 2007
    ..These findings offer an important new tool for the study of normal and malignant breast stem cells and facilitate the clinical application of stem cell concepts...
  97. ncbi request reprint Basal and luminal breast cancers: basic or luminous? (review)
    Daniel Birnbaum
    Laboratoire d Oncologie Moleculaire, Institut Paoli Calmettes and UMR599 INSERM, 13009 Marseille, France
    Int J Oncol 25:249-58. 2004
    ..The combined effects of these progresses on our understanding of breast cancer biology should have major consequences on the way this disease is managed...